Loading
A phase 2 trial of Dacarbazine, Temozolomide, Paclitaxel / nab-paclitaxel in melanoma, run by Suzhou BlueHorse Therapeutics Co., Ltd., now recruiting.
A Phase II Trial of LM103 in Advanced Melanoma is a phase 2 interventional study registered as NCT07310784 by Suzhou BlueHorse Therapeutics Co., Ltd., with 92 participants planned, started 2025-12-16 and due to reach its primary completion in 2027-12-31. Interventions recorded: LM103 TILs Injection, Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin. Conditions listed: Advanced Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dacarbazine, Temozolomide, Advanced melanoma (unresectable stage III and stage IV), Paclitaxel / nab-paclitaxel.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Temozolomide, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Temozolomide, Cisplatin.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/